Valneva to supply Covid-19 vaccine doses to EU
French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001.
French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001.
Pfizer and its partner BioNTech have announced that the US government has purchased additional paediatric doses of their Covid-19 vaccine, as it prepares for paediatric vaccinations.
Biocon Biologics Limited (BBL), a subsidiary of Biocon, and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd., has announced a strategic alliance.
Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19.
The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have signed an agreement with Regeneron Pharmaceuticals to buy additional doses of the firm’s Covid-19 antibody cocktail, REGEN-COV (casirivimab and imdevimab).
The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate.
GlaxoSmithKline (GSK) and Vir Biotechnology have announced a joint procurement agreement with the European Commission for the supply of up to 220,000 doses of sotrovimab to treat Covid-19 patients.
The European Commission has purchased an additional 150 million Moderna’s Covid-19 vaccine doses, bringing its confirmed order commitment to 460 million doses.
Court of First Instance of Brussels has ordered AstraZeneca to deliver 50 million doses of its Covid-19 vaccine to Europe by 27 September this year.
Merck, called MSD outside the US and Canada, has signed an agreement with the US government to supply about 1.7 million courses of molnupiravir (MK-4482) for the treatment of mild to moderate Covid-19.